TLDR:
– Korio, Inc. secures Series A funding led by BIP Ventures
– Funding driven by strong market demand for Korio’s RTSM platform
Korio, Inc., a leading Randomization & Trial Supply Management (RTSM) technology company, has successfully completed its Series A funding round. The round was led by BIP Ventures, with participation from existing investors Excelerate Health Ventures and Boston Millennia Partners, among others. This funding comes on the heels of Korio’s initial seed funding in September 2023, showcasing the market’s positive response to the company’s innovative approach to addressing RTSM challenges in clinical trials.
Investors like BIP Ventures see the potential in Korio’s RTSM platform to reshape the industry by providing flexible and quality-focused solutions. The platform has already garnered significant customer adoption, with trial sponsors praising its ability to adapt to unique study requirements, ultimately leading to improved RTSM experiences. The investment will be utilized to fund Korio’s global expansion efforts and enhance their client services and support team.
Korio’s Co-founder and CEO, Ryan Keane, expressed gratitude for the trust customers have shown in the company, leading to this new funding. He highlighted the company’s commitment to meeting the increasing demand for their solution and continuing to innovate based on customer feedback. With a focus on providing top-notch client services and support, Korio aims to further solidify its position as a leader in the RTSM space.
